Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: A meta-analysis

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Annunziata, Salvatore ^a   Caldarella, Carmelo ^a   Pizzuto, Daniele Antonio ^a   Galiandro, Federica ^a   Sadeghi, Ramin ^b   Giovanella, Luca ^c   Treglia, Giorgio ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

BILE DUCT CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; IMAGE ANALYSIS; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; QUALITATIVE ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DIAGNOSTIC USE; INTRAHEPATIC BILE DUCT; MULTIMODAL IMAGING; PATHOLOGY; PROCEDURES;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FLUORODEOXYGLUCOSE F18; HUMANS; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 84901797279     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/247693     Document Type: Review

References (26)

1. 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease. Clinical Nuclear Medicine 2013 38 e106 e111
2. 18F-fluorodeoxyglucose positron emission tomography-computed tomography is a prognostic value for survival in bile duct and gallbladder cancer. The Korean Journal of Gastroenterology 2013 62 227 233
3. Albazaz R., Patel C. N., Chowdhury F. U., Scarsbrook A. F., Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours. Insights Imaging 2013 4 691 700
4. Treglia G., Cason E., Fagioli G., Recent applications of nuclear medicine in diagnostics (first part). Italian Journal of Medicine 2010 4 2 84 91 2-s2.0-77957865813 10.1016/j.itjm.2010.03.001
5. Egger M., Smith G. D., Schneider M., Minder C., Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997 315 7109 629 634 2-s2.0-0030922816 (Pubitemid 27387172)
6. Fritscher-Ravens A., Bohuslavizki K. H., Broering D. C., Jenicke L., SchÄfer H., Buchert R., Rogiers X., Clausen M., FDG PET in the diagnosis of hilar cholangiocarcinoma. Nuclear Medicine Communications 2001 22 12 1277 1285 2-s2.0-0035203796 10.1097/00006231-200112000-00002 (Pubitemid 33116535)
7. 18F]fluoro-2- deoxyd-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001 33 5 1029 1035 2-s2.0-0035028577 10.1053/jhep.2001.23912 (Pubitemid 32378198)
8. 18F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. European Journal of Nuclear Medicine 2002 29 8 1047 1054 2-s2.0-0036326797 10.1007/s00259-002-0852-z
9. 18F-FDG PET in intrahepatic cholangiocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging 2003 30 11 1467 1472 2-s2.0-0242270687 (Pubitemid 37356113)
10. Anderson C. D., Rice M. H., Pinson C. W., Chapman W. C., Chari R. S., Delbeke D., Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. Journal of Gastrointestinal Surgery 2004 8 1 90 97 2-s2.0-1642464588 10.1016/j.gassur.2003.10.003 (Pubitemid 38117282)
11. 18F-FDG PET/CT: preliminary results for 22 patient studies. Journal of Nuclear Medicine 2005 46 7 1158 1163 2-s2.0-23844446493 (Pubitemid 43741078)
12. Wakabayashi H., Akamoto S., Yachida S., Okano K., Izuishi K., Nishiyama Y., Maeta H., Significance of fluorodeoxyglucose PET imaging in the diagnosis of malignancies in patients with biliary stricture. European Journal of Surgical Oncology 2005 31 10 1175 1179 2-s2.0-29244484432 10.1016/j.ejso.2005.05.012 (Pubitemid 41819204)
13. Petrowsky H., Wildbrett P., Husarik D. B., Hany T. F., Tam S., Jochum W., Clavien P.-A., Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. Journal of Hepatology 2006 45 1 43 50 2-s2.0-33744920603 10.1016/j.jhep.2006.03.009 (Pubitemid 43850623)
14. Prytz H., Keiding S., Björnsson E., Broomé U., Almer S., Castedal M., Munk O. L., Almer S., Bergquist A., Broomé U., Glaumann H., Björnsson E., Olsson R., Wallerstedt S., Danielsson Å., Hultcrantz R., Lindgren S., Verbaan H., Lööf L., Prytz H., Sandberg- Gertzén H., Sangfelt P.-G., Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 2006 44 6 1572 1580 2-s2.0-33845600792 10.1002/hep.21433 (Pubitemid 44953662)
15. Nishiyama Y., Yamamoto Y., Kimura N., Miki A., Sasakawa Y., Wakabayashi H., Ohkawa M., Comparison of early and delayed FDG PET for evaluation of biliary stricture. Nuclear Medicine Communications 2007 28 12 914 919 2-s2.0-37349072139 10.1097/MNM.0b013e3282f1ac85 (Pubitemid 350306783)
16. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. Journal of the American College of Surgeons 2008 206 1 57 65 2-s2.0-37249057824 10.1016/j.jamcollsurg.2007.07.002 (Pubitemid 350267250)
17. 18F-fluorodeoxyglucose PET: prospective comparison with PET+CT, MDCT and histopathology. European Radiology 2008 18 12 2841 2847 2-s2.0-56349114895 10.1007/s00330-008-1062-2
18. 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. American Journal of Gastroenterology 2008 103 5 1145 1151 2-s2.0-43549085957 10.1111/j.1572-0241.2007.01710.x (Pubitemid 351677961)
19. Li J., Kuehl H., Grabellus F., Müller S. P., Radunz S., Antoch G., Nadalin S., Broelsch C. E., Gerken G., Paul A., Kaiser G. M., Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. Journal of Surgical Oncology 2008 98 6 438 443 2-s2.0-55749088949 10.1002/jso.21136
20. 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. Journal of Gastroenterology and Hepatology 2008 23 5 759 765 2-s2.0-42049101480 10.1111/j.1440-1746.2007.05173.x (Pubitemid 351519420)
21. 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. Journal of Gastroenterology 2010 45 5 560 566 2-s2.0-77953322456 10.1007/s00535-009-0188-6
22. Alkhawaldeh K., Faltten S., Biersack H.-J., Ezziddin S., The value of F-18 FDG PET in patients with primary sclerosing cholangitis and cholangiocarcinoma using visual and semiquantitative analysis. Clinical Nuclear Medicine 2011 36 10 879 883 2-s2.0-80053590905 10.1097/RLU.0b013e3182291a64
23. 18F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer. Journal of Hepato-Biliary- Pancreatic Sciences 2011 18 1 39 46 2-s2.0-79957851828 10.1007/s00534-010-0293-1
24. Ruys A. T., Bennink R. J., Van Westreenen H. L., Engelbrecht M. R., Busch O. R., Gouma D. J., van Gulik T. M., FDG-positron emission tomography/computed tomography and standardized uptake value in the primary diagnosis and staging of hilar cholangiocarcinoma. HPB 2011 13 4 256 262 2-s2.0-79952933965 10.1111/j.1477-2574.2010.00280.x
25. Yamada I., Ajiki T., Ueno K., Sawa H., Otsubo I., Yoshida Y., Shinzeki M., Toyama H., Matsumoto I., Fukumoto T., Nakao A., Kotani J., Ku Y., Feasibility of (18)F-fluorodeoxyglucose positron-emission tomography for preoperative evaluation of biliary tract cancer. Anticancer Research 2012 32 5105 5110
26. Treglia G., Sadeghi R., Meta-analyses and systematic reviews on PET and PET/CT in oncology: the state of the art. Clinical and Translational Imaging 2013 1 73 75